N4 Pharma “at the right place at the right time and not by luck, but by design” says SP Angel (LON:N4P) 26 July 2021
Jarvis Securities expecting similar levels of market activity to those in the first half (LON:JIM) 26 July 2021
Fidelity Special Values “Outstanding Performance” Beats Nasdaq Composite Index I Latest Research 15 January 2026
Real Estate Credit Investments Gains Strong Shareholder Backing Following 2025 Continuation Vote (LON:RECI) 14 January 2026
Cranswick PLC (CWK.L) Stock Analysis: Exploring a 14.75% Potential Upside in the Defensive Food Sector 21 January 2026
Computacenter PLC (CCC.L) Stock Analysis: Navigating a 4.27% Upside Potential with Robust Growth and Dividend Appeal 21 January 2026
Chrysalis Investments Limited (CHRY.L) Stock Analysis: Unlocking a 28.75% Potential Upside with Strong Buy Ratings 21 January 2026
Coats Group PLC (COA.L) Stock Analysis: Unpacking a 40.78% Potential Upside for Investors 21 January 2026
N4 Pharma “at the right place at the right time and not by luck, but by design” says SP Angel (LON:N4P) 26 July 2021
Jarvis Securities expecting similar levels of market activity to those in the first half (LON:JIM) 26 July 2021
Fidelity Special Values “Outstanding Performance” Beats Nasdaq Composite Index I Latest Research 15 January 2026
Real Estate Credit Investments Gains Strong Shareholder Backing Following 2025 Continuation Vote (LON:RECI) 14 January 2026
Cranswick PLC (CWK.L) Stock Analysis: Exploring a 14.75% Potential Upside in the Defensive Food Sector 21 January 2026
Computacenter PLC (CCC.L) Stock Analysis: Navigating a 4.27% Upside Potential with Robust Growth and Dividend Appeal 21 January 2026
Chrysalis Investments Limited (CHRY.L) Stock Analysis: Unlocking a 28.75% Potential Upside with Strong Buy Ratings 21 January 2026
Coats Group PLC (COA.L) Stock Analysis: Unpacking a 40.78% Potential Upside for Investors 21 January 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: A Biotech with a 44% Upside Potential 16 December 2025
NewAmsterdam Pharma (NAMS) Investor Outlook: 33.62% Upside Potential with Promising Drug Pipeline 16 December 2025
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Unlocking a 125.92% Potential Upside 16 December 2025
Tarsus Pharmaceuticals, Inc. (TARS): Analyst Consensus and Growth Potential Point to Promising Upside 16 December 2025
IDEAYA Biosciences, Inc. (IDYA) Investor Outlook: Potential Upside of Nearly 49% Amidst Strong Buy Ratings 16 December 2025
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 44% Potential Upside in the Biotech Sector 16 December 2025
Kymera Therapeutics, Inc. (KYMR) Investor Outlook: Exploring a 33% Upside with Promising Buy Ratings 16 December 2025
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: A 27% Upside Potential with Strong Buy Ratings 16 December 2025
ImmunityBio, Inc. (IBRX) Investor Outlook: Examining a 368% Potential Upside with Promising Biotech Innovations 16 December 2025
MoonLake Immunotherapeutics (MLTX) Stock Report: A Biotechnology Pioneer with Promising Upside 16 December 2025
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 171% Upside 16 December 2025
Beam Therapeutics Inc. (BEAM): Analyst Consensus Points to 71% Upside Potential for Biotech Innovator 16 December 2025
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a Potential 51.79% Upside in the Biotech Sector 16 December 2025
BGM Group Ltd. (BGM): Assessing the Impact of a Dramatic Revenue Decline on Future Prospects 16 December 2025
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Navigating a 19.65% Potential Upside in Biotech 16 December 2025
NovoCure Limited (NVCR) Stock Analysis: A Potential 91% Upside for This Innovative Oncology Device Maker 16 December 2025
Premier, Inc. (PINC) Stock Report: Navigating Healthcare with a 2.97% Dividend Yield 16 December 2025
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: A 27.96% Upside Potential Awaits Investors 16 December 2025
Symphony Environmental “Meditech a fantastic validation” say Hybridan (Analyst Interview) 9 August 2021
Fidelity Special Values outperforms the UK All-Share by 4.9% per annum (Analyst Interview) 6 August 2021
Clarkson Plc appoints Bloomberg’s Constantin Cotzias as Independent Non-Executive Director 5 August 2024
Wizz Air reports July 2024 passenger and CO2 emission statistics amid GTF engine groundings 2 August 2024
Senior Plc signs Deutsche Aircraft contract for the advanced, sustainable D328eco platform 2 August 2024
N4 Pharma “at the right place at the right time and not by luck, but by design” says SP Angel (LON:N4P) 26 July 2021
Jarvis Securities expecting similar levels of market activity to those in the first half (LON:JIM) 26 July 2021
Fidelity Special Values “Outstanding Performance” Beats Nasdaq Composite Index I Latest Research 15 January 2026
Real Estate Credit Investments Gains Strong Shareholder Backing Following 2025 Continuation Vote (LON:RECI) 14 January 2026
Cranswick PLC (CWK.L) Stock Analysis: Exploring a 14.75% Potential Upside in the Defensive Food Sector 21 January 2026
Computacenter PLC (CCC.L) Stock Analysis: Navigating a 4.27% Upside Potential with Robust Growth and Dividend Appeal 21 January 2026
Chrysalis Investments Limited (CHRY.L) Stock Analysis: Unlocking a 28.75% Potential Upside with Strong Buy Ratings 21 January 2026
Coats Group PLC (COA.L) Stock Analysis: Unpacking a 40.78% Potential Upside for Investors 21 January 2026
